Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Diaphragm Injury

In brief

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Key facts

Study ID

NCT03681275

Run by

Stanford University

People needed

70

Starts

2019-09-03

Expected to finish

2026-11-30

Last updated by the study team

2024-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing esophagectomy

You may not qualify if…

• Patients with more than mild pulmonary dysfunction
• Patients with any neuromuscular disease that might compromise diaphragm function
• Patients with abnormal liver or kidney function
• Patients taking any immunosuppressant medication (including prednisone) or antifungal medications
• History of tuberculosis
• Weight loss of >5% of body weight over previous 6 months
• Pregnancy

Where it is running

• Stanford University Medical Center — Stanford, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.